Is work–family balance more than conflict and enrichment?

由 Carlson, Dawn S., Grzywacz, Joseph G., Zivnuska, Suzanne
出版 2009

Health and Turnover of Working Mothers After Childbirth Via the Work–Family Interface: An Analysis Across Time

由 Carlson, Dawn S., Grzywacz, Joseph G., Ferguson, Merideth, Hunter, Emily M., Clinch, C. Randall, Arcury, Thomas A.
出版 2011

Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

由 Chiu, Yi-Lin, LoRusso, Patricia, Hosmane, Balakrishna, Ricker, Justin L., Awni, Walid, Carlson, Dawn M.
出版 2013

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

由 Rosenson, Robert S., Carlson, Dawn M., Kelly, Maureen T., Setze, Carolyn M., Hirshberg, Boaz, Stolzenbach, James C., Williams, Laura A.
出版 2010

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in...

由 Davidson, Michael, Rosenson, Robert S., Maki, Kevin C., Nicholls, Stephen J., Ballantyne, Christie M., Setze, Carolyn, Carlson, Dawn M., Stolzenbach, James
出版 2012

Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies

由 Pepine, Carl J., Jacobson, Terry A., Carlson, Dawn M., Kelly, Maureen T., Setze, Carolyn M., Gold, Alex, Stolzenbach, James C., Williams, Laura A.
發表在 Clin Cardiol (2010)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

由 Asahina, Hajime, Tamura, Yosuke, Nokihara, Hiroshi, Yamamoto, Noboru, Seki, Yoshitaka, Shibata, Takashi, Goto, Yasushi, Tanioka, Maki, Yamada, Yasuhide, Coates, Andrew, Chiu, Yi-Lin, Li, Xiaohui, Pradhan, Rajendra, Ansell, Peter J., McKeegan, Evelyn M., McKee, Mark D., Carlson, Dawn M., Tamura, Tomohide
出版 2012

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Renal Cell Cancer (RCC) after Sunitinib Failure

由 Tannir, Nizar M., Wong, Yu-Ning, Kollmannsberger, Christian K., Ernstoff, Marc S., Perry, David J., Appleman, Leonard J., Posadas, Edwin M., Cho, Daniel, Choueiri, Toni K., Coates, Andrew, Gupta, Neeraj, Pradhan, Rajendra, Qian, Jiang, Chen, Jihong, Scappaticci, Frank A., Ricker, Justin L., Carlson, Dawn M., Michaelson, M. Dror
出版 2011

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

由 Cainap, Calin, Qin, Shukui, Huang, Wen-Tsung, Chung, Ik Joo, Pan, Hongming, Cheng, Ying, Kudo, Masatoshi, Kang, Yoon-Koo, Chen, Pei-Jer, Toh, Han-Chong, Gorbunova, Vera, Eskens, Ferry A.L.M., Qian, Jiang, McKee, Mark D., Ricker, Justin L., Carlson, Dawn M., El-Nowiem, Saied
發表在 J Clin Oncol (2015)

Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer

由 Ramalingam, Suresh S., Shtivelband, Mikhail, Soo, Ross A., Barrios, Carlos H., Makhson, Anatoly, Segalla, José G.M., Pittman, Kenneth B., Kolman, Petr, Pereira, Jose R., Srkalovic, Gordan, Belani, Chandra P., Axelrod, Rita, Owonikoko, Taofeek K., Qin, Qin, Qian, Jiang, McKeegan, Evelyn M., Devanarayan, Viswanath, McKee, Mark D., Ricker, Justin L., Carlson, Dawn M., Gorbunova, Vera A.
發表在 J Clin Oncol (2015)